

1 **Reporting of Retrospective Registration in Clinical Trial Publications: a Cross-Sectional Study of**
2 **German Trials**

3

4 Martin Haslberger* (MH), <https://orcid.org/0000-0002-8067-2856>, [martin.haslberger@bih-](mailto:martin.haslberger@bih-charite.de)
5 [charite.de](mailto:martin.haslberger@bih-charite.de)

6 Stefanie Gestrich (SG), stefanie.gestrich@charite.de

7 Daniel Strech (DS), <https://orcid.org/0000-0002-9153-079X>, daniel.strech@bih-charite.de

8

9

10 Berlin Institute of Health at Charité – Universitätsmedizin Berlin, QUEST Center for Responsible
11 Research, Charitéplatz 1, 10117 Berlin, Germany

12

13 * Corresponding author

14

15 **Keywords:** Clinical Trials, Trial Registration, Reporting, Retrospective Registration

16

17

18 Abstract

19 **Objective:** Prospective registration has been widely implemented and accepted as a best practice in
20 clinical research, but retrospective registration is still commonly found. We assessed to what extent
21 retrospective registration is reported transparently in journal publications, and investigated factors
22 associated with transparent reporting.

23 **Design:** We used a dataset of trials registered in ClinicalTrials.gov or Deutsches Register Klinischer
24 Studien, with a German University Medical Center as the lead center, completed 2009–2017, and
25 with a corresponding peer-reviewed results publication. We extracted all registration statements
26 from results publications of retrospectively registered trials and assessed whether they mention or
27 justify the retrospective registration. We analyzed associations of retrospective registration and
28 reporting thereof with registration number reporting, International Committee of Medical Journal
29 Editors (ICMJE) membership/-following and industry sponsorship using chi-squared or Fisher exact
30 test.

31 **Results:** In the dataset of 1927 trials with a corresponding results publication, 956 (53.7%) were
32 retrospectively registered. Of those, 2.2% (21) explicitly report the retrospective registration in the
33 abstract and 3.5% (33) in the full text. In 2.1% (20) of publications, authors provide an explanation
34 for the retrospective registration in the full text. Registration numbers were significantly
35 underreported in abstracts of retrospectively registered trials compared to prospectively registered
36 trials. Publications in ICMJE member journals did not have statistically significantly higher rates of
37 both prospective registration and disclosure of retrospective registration, and publications in
38 journals claiming to follow ICMJE recommendations showed statistically significantly lower rates
39 compared to non-ICMJE-following journals. Industry sponsorship of trials was significantly associated
40 with higher rates of prospective registration, but not with transparent registration reporting.

41 **Conclusions:** Contrary to ICMJE guidance, retrospective registration is disclosed and explained only
42 in a small number of retrospectively registered studies. Disclosure of the retrospective nature of the
43 registration would require a brief statement in the manuscript and could be easily implemented by
44 journals.

45

46

47

48

49 Strengths and limitations of this study

- 50 • We use a large, high-quality dataset of all trials conducted at German university medical
51 centers and registered in two registries, with results publications determined by an
52 extensive manual screening process.
 - 53 • We consider a period of nine years (2009 – 2017) and describe the development of reporting
54 practices over time
 - 55 • This study only includes trials led by German university medical centers, reflecting German
56 regulatory standards.
- 57

58 Introduction

59 Prospective registration of clinical trials (i.e., registration before enrollment of the first participant) is
60 an important practice to reduce biases in their conduct and reporting (1). A number of ethical and
61 legal documents call for prospective registration: The Declaration of Helsinki (2) and the World
62 Health Organization registry standards (3) state that prospective registration and results reporting of
63 clinical trials are an ethical responsibility. European law, for example, explicitly mandates
64 prospective registration of pharmaceutical trials (4). In addition, many journals, via the International
65 Committee of Medical Journal Editors (ICMJE), encourage or require prospective registration with an
66 appropriate registry before the first participant is enrolled for all trials they publish, as well as the
67 reporting of trial registration numbers (TRNs) in publications for better findability (5,6). Similarly,
68 reporting guidelines such as Consolidated Standards of Reporting Trials (CONSORT) (7) and Good
69 Publication Practice 3 (GPP3) (8) recommend the reporting of trial registration numbers.
70 Prospective registration has been widely implemented and advocated for many reasons: to detect
71 and mitigate publication bias (i.e., the non-reporting of studies, or aspects of studies, that did not
72 yield a positive result) and selective reporting (i.e., the selective reporting of only statistically
73 significant primary outcomes). Prospective registration allows for public scrutiny of trials,
74 identification of research gaps and to support the coordination of efforts by preventing unnecessary
75 duplication (9). When trials are registered retrospectively, i.e., their registry entry is created after
76 study start, this undermines the many of the reasons for registration. While prospective registration
77 has increased over the past decade, retrospective registration is still widespread (10–14). Some
78 registries, such as Deutsches Register Klinischer Studien (DRKS) or the WHO’s International Clinical
79 Trials Registry Platform, explicitly mark retrospectively registered entries as such, whereas others,
80 such as ClinicalTrials.gov, do not. While some journal editors allow retrospectively registered trials to
81 be published, others do not. Journals following ICMJE guidance should in principle mandate
82 prospective registration, but this principle is not always enforced (12,15,16). According to ICMJE
83 guidance, journals should publish retrospectively registered studies only in exceptional cases, noting
84 that “authors should indicate in the publication when registration was completed and why it was
85 delayed. Editors should publish a statement indicating why an exception was allowed.” (5) This was
86 investigated by previous studies which found that such reporting rarely happens (17,18).
87 Our study aims to investigate the conduct of retrospective registration and its transparent reporting
88 in a larger sample. In a previous study in a cohort of 1509 trials conducted at German University
89 Medical Centers (UMC), registered in DRKS or ClinicalTrials.gov, and reported as complete between
90 2009-2013, 75% were registered retrospectively (19). This rate dropped to 46% for the 1658 trials
91 completed between 2014-2017 (20). Using the data from these two studies on trials registered in
92 two large registries, led by German UMCs, completed between 2009 and 2017, and with at least one
93 available peer-reviewed results publication (19,20), we investigate whether and how authors report
94 retrospective registration in the results publication. We also explore how retrospective registration
95 is associated with other practices such as TRN reporting.

96

97 Methods

98 *Data sources and sample.* We based our sample on two related projects that were conducted at our
99 research group (19,20). The projects have drawn a full sample (n = 3113) of registry entries for
100 interventional studies reported as complete between 2009 and 2017, led by a German UMC and
101 registered in one of two registries: DRKS, which is the WHO primary trial registry for Germany, and
102 ClinicalTrials.gov, which is also routinely used in Germany to register clinical research and accepted

103 by the ICMJE. Our dataset also includes the earliest results publications found for 68.4% (2129/3113)
104 of the trials, which were manually identified in different stages until September 1st, 2020. We
105 retrieved the combined data from the two projects from a GitHub repository
106 (<https://github.com/maia-sh/intoalvalue-data>, accessed 22.02.2022). The final dataset is publicly
107 available (21).

108 *Eligibility criteria.* We included any trial that [1] was registered as an interventional study in either
109 the ClinicalTrials.gov or the DRKS database, [2] was completed between 2009 and 2017, [3] reports a
110 German UMC listed as the responsible party or lead sponsor, or with a principal investigator from a
111 German UMC, [4] has published results in a peer-reviewed journal. Detailed descriptions of how
112 these variables were derived are provided in the original publications of the dataset (19,20).

113 Retrospective registration was determined based on the registration and study start dates in the
114 registry entries: dates were set to the first of the respective month and studies with a registration
115 date more than one month after start date counted as retrospectively registered. For trials that were
116 registered in both registries, we kept the entry that was created earlier.

117 *Data extraction.* For all retrospectively registered trials, we manually searched the abstract and the
118 full text of the publications, including editorial statements, whether they reported

- 119 • the fact that the study was registered (binary),
- 120 • a trial registration number (binary),
- 121 • the exact wording used to report the registration, including any provided registration
122 numbers (free text),
- 123 • the date of the retrospective registration (binary), and
- 124 • the fact that the study was retrospectively registered (binary).
- 125 • We also assessed whether (binary) and how authors justified or explained the retrospective
126 registration (free text).

127 One rater (MH) used the keywords “regist”, “nct”, “drks”, “eudra”, “retro”, “delay”, and “after” to
128 search for registration numbers and wording pointing to retrospective registration in all publications.
129 We considered a retrospective registration statement transparent if the authors explicitly mentioned
130 that the registration was retrospective, e.g., “this study was retrospectively registered in [registry],
131 [TRN]”. Reporting of the registration date alone was not considered as transparent reporting of
132 retrospective registration, except if the date of registration was mentioned in combination with the
133 study start date in the same paragraph.

134 *ICMJE journals.* We created additional variables for whether journals are ICMJE members or follow
135 the ICMJE recommendations (22).

136 *Cross-registrations.* We classified all retrospectively registered studies in our sample that also report
137 a registration in EudraCT in the publication as prospective, as registrations on the platform are
138 required prior to the approval of regulatory agencies or research ethics committees (4).

139 *Reliability assessment of ratings.* To assess the reliability of the data extraction, another rater (SG)
140 performed three validation steps: first, a sample of 100 publications was screened using the same
141 extraction form, during the main screening to refine category definitions. Second, another sample of
142 100 publications for which no registration number reporting was noted by MH to check for false
143 negative ratings. Third, all cases with either date, or reporting of retrospective registration or
144 justification were screened, to check for false positives.

145 *Analyses*

146 *Associations between prospective registration and other variables.* To test the strength of the
147 associations between prospective registration and three variables, we used Pearson’s chi-squared

148 independence test. These variables were (1) publication in a ICMJE member journal or a journal
149 following ICMJE recommendations, (2) reporting of a registration number, and (3) industry funding.
150 *Associations between reporting of retrospective registration and other variables.* To test the strength
151 of the associations between the reporting of retrospective registration and two binary variables, we
152 used Fisher's exact test, as case numbers were low. These variables are (1) publication in a ICMJE
153 member journal or a journal following ICMJE recommendations, and (2) industry funding.

154 *Software*

155 We used Microsoft Excel for data collection and R (version 4.0.3) for data analysis and visualization.

156

157 *Reporting*

158 We checked our manuscript against the STROBE checklist (supplementary Table 1) (23).

159

160 *Patient and Public Involvement*

161 No patient involved.

162

163 **Results**

164 *Sample of retrospectively registered trials.* After applying the above-mentioned exclusion criteria,
165 1932 registered studies with an associated results publication remained. Of these, 1038 (54%) were
166 retrospectively registered according to the information provided in ClinicalTrials.gov and DRKS. We
167 screened these 1038 studies for our analysis. Five of the publications were excluded as they were
168 mislabeled as results publications in the dataset. Another 77 (8%) of the publications provided a
169 EudraCT number, in which case we reclassified the study as prospectively registered, leaving 956
170 studies. For statistical comparisons, we used the studies classified as prospectively registered
171 (n=971) in the dataset as a control group. A flowchart of this study selection is provided in Figure 1.
172 Basic characteristics of included trials are available in supplementary Table 2.

173

174 *Retrospective registration.* Figure 2 shows the extent of retrospective registration over time, which
175 has been falling steadily from 100% in 2004 to 25% in 2017.

176 We describe associations between prospective registration and previously defined binary variables
177 in Table 1: We found no statistically significant association between publication in ICMJE member
178 journals and prospective registration ($p=0.10$). Similarly, we found no statistically significant
179 association with prospective registration when also including publication in journals reporting to
180 follow ICMJE recommendations ($p=0.47$). It is important to note here that the information on ICMJE-
181 following is based on journals' requests to be included on the ICMJE website as a journal following
182 the ICMJE's recommendations (22), therefore our results suggest that journals requesting to be
183 listed on the site often do not enforce the recommendations strongly. However, there are other
184 journals, such as many PLOS journals, that are not featured on the ICMJE site, but implement the
185 recommendations. Retrospectively registered trials, compared to prospectively registered trials
186 significantly underreported registration numbers in the abstract ($p = 0.0007$). Industry sponsorship
187 of trials was associated with prospective registration ($p = 0.002$). In 31% (294/956) of trials,
188 registration occurred between study completion and publication (median 370 days before
189 publication). Another 3% (25/956) of trials were registered after publication (median 249 days after
190 publication).

191

192 *Table 1: Associations between prospective registration and other variables*

Variable (Yes/No)		n (%) prospectively registered	P-value (Chi-sq.)
ICMJE member journal	Y	28 (63.6%)	p = 0.10
	N	943 (50.1%)	
ICMJE member/following journal	Y	329 (49.2%)	p = 0.47
	N	642 (51.0%)	
TRN reporting in abstract	Y	404 (55.4%)	p = 0.0007
	N	567 (47.3%)	
Industry sponsorship	Y	163 (59.3%)	p = 0.002
	N	808 (48.9%)	

193

194 *Reporting of registration.* Table 2 summarizes the prevalence of reporting of trial registration and
 195 the reporting of retrospective registration. In 82% (783/956) of the remaining results publications of
 196 retrospectively registered trials, the registration was explicitly reported in either the abstract or the
 197 full text. In all except four of these publications, the registration was mentioned by providing the
 198 registration number. In the other cases, the registration was mentioned but without reporting a
 199 registration number.

200

201 *Table 2: Number of retrospectively registered trials and prevalence of key retrospective registration*
 202 *reporting practices.*

203 * "other" includes footnotes, sidebars, etc.

	n	% (of total)
Total: Retrospectively registered trials	956	100.0%
Registration reported	783	81.9%
Registration number reported	779	81.5%
<i>in abstract</i>	325	34.0%
<i>in full-text</i>	535	56.0%
<i>in other*</i>	134	14.0%
Registration date reported	67	7.0%
<i>in abstract</i>	45	4.7%
<i>in full-text</i>	32	3.3%
Retrospective registration addressed	47	4.9%
<i>in abstract</i>	21	2.2%
<i>in full-text</i>	33	3.5%
Retrospective registration justified/explained	20	2.1%
<i>in abstract</i>	0	0.0%
<i>in full-text</i>	20	2.1%

204

205 *Reporting of retrospective registration.* The rate of trials for which retrospective registration is
 206 reported transparently increased over the last years up to 15% in 2020 (Figure 3). Overall, among all
 207 956 retrospectively registered clinical studies, five percent (47) mention explicitly that this
 208 registration was retrospective in the abstract or full text (see Table 2). Among those cases, 20 give

209 some explanation or justification for why registration was retrospective. In seven percent (67) of
 210 cases, the authors reported the registration date alongside the registration statement, but in 35 of
 211 those, the date was provided without giving the necessary context that the registration was
 212 retrospective.
 213 Publications in ICMJE member journals did not have a statistically significantly higher rate of
 214 reporting of retrospective registration (13% vs. 5%, $p = 0.18$), whereas publications in ICMJE member
 215 or -following journals had a significantly lower rate (2% vs. 7%, $p = 0.004$). We found no association
 216 with transparent reporting of retrospective registration for industry sponsored trials (2% vs. 5%, $p =$
 217 0.16) (Table 3).

218

219 *Table 3: Associations between transparent reporting of retrospective registration and other variables*

Variable (Yes/No)		n (%) reporting RR	P-value (Fisher test)
ICMJE member journal	Y	2 (12.5%)	$p = 0.18$
	N	45 (4.8%)	
ICMJE member/following journal	Y	7 (2.1%)	$p = 0.004$
	N	40 (6.5%)	
Industry sponsorship	Y	2 (1.8%)	$p = 0.16$
	N	45 (5.3%)	

220

221 *Justifications of retrospective registration.* In 20 cases in which the retrospective nature of the
 222 registration was reported, the authors provided further information explaining or justifying the
 223 retrospective registration. Notably, 14 of the 20 studies (70%) that justified the retrospective
 224 registration were published in a single journal, PLOS ONE. Table 4 shows the main themes present in
 225 authors' explanations, with text examples.

226

227 *Table 4. Main themes identified from authors' explanations of retrospective reporting and example*
 228 *statements.*

Theme	Example(s)
Unawareness of registration policy	<p>"At the time when the trial was started, the initiators of this study were unfortunately unaware of the policy of the International Committee of Medical Journal Editors (ICMJE), which requires prospective registration of all interventional clinical trials. As soon as we became aware of this policy, we registered the trial." (doi: 10.1371/journal.pone.0146678)</p> <p>"The reason for retrospectively registering the study was that the study authors were not aware of the recommendation to register diagnostic accuracy studies before this date." (doi: 10.1371/journal.pone.0199345)</p>
Delays by the registry	<p>"Registration of the study was applied for in April 2015. All queries from the DRKS were answered until the 31st August 2015 except the planned inclusion date of the first patient (first-patient-in), which was correct in the DRKS registry on 1st December 2015. Confirmation of registration occurred on 4th December 2015. The first patient was recruited and randomized into the study on 20th October 2015. Until 4th December 2015 eight patients were randomized into the trial." (doi: 10.1371/journal.pone.0229898)</p>
Not obligatory at the time	<p>"At the time of submission of the study protocol, the Ethics Committee did not require registration for feasibility or proof of concept studies. The study was registered in ClinicalTrials.gov (NCT02196545) in July 2014 in preparation of a manuscript for publication of the data. The authors confirm that all ongoing and related trials for this intervention are registered." (doi: 10.1371/journal.pone.0121478)</p>

	„It was not registered at a clinical trial register, because at the time of setup in 2003, such a registration was not obligatory.“ (doi: 10.2174/1874325001307010133)
Not obligatory for the intervention	“According to national laws it is stipulated to inform the respective ethics committee, but it was not necessary to register the study in an official registry or to obtain an ethics committee vote, because it was an expanded access study (Heilver such). Despite this, we prospectively obtained a vote of the ethics committee. Study design and patient information form were approved by the local ethics committee (ethics committee of the regional medical association; approval no. EK-BR-50/10-1, date of approval December 10th, 2010). In addition, the study was registered at www.clinicaltrials.gov (ID no. NCT02168790).“ (doi: 10.1371/journal.pone.0125035)
Miscommunication between investigators	<p>“The time of first registration was June 17, 2013, and final approved trial registration was July 1, 2013. First patient inclusion was in July 2012 at the Heart Center Leipzig University Hospital, Leipzig, Germany. Thus, there was a delay between first patient inclusion and trial registration that was the result of a misunderstanding between the principal investigator of the trial, Dr Thiele, and the first author, Dr Fuernau, who was responsible for clinical project coordination at the investigator’s site at the Heart Center Leipzig University of Leipzig. According to initial communication, registration had to be performed by Dr Fuernau. When the study principal investigator recognized that it had not been performed, we immediately registered the trial at http://www.ClinicalTrials.gov. At this time, only 7 patients at the Heart Center Leipzig University Hospital had been included in the trial.“ (doi: 10.1161/CIRCULATIONAHA.117.032722)</p> <p>„[...] there was a delay of trial registration before first patient inclusion which was induced by a misunderstanding between the project coordination for the EU grant (at this time gabo:mi, later on ARTTIC) and the clinical project coordination at the investigator’s site at the Heart Center Leipzig - University of Leipzig. According to initial communication registration should be performed by gabo:mi. When the study coordinator recognized that it has not been performed we immediately registered it at clinicaltrials.gov. At this time only 13 patients at the Heart Center Leipzig University Hospital (and no other study site) have been included into the trial.“ (doi: 10.1056/NEJMoa1710261)</p>
Publication	“Registration was done after the study has been conducted and the results suggested a publication and further continuation of this research.“ (doi: 10.1186/s12903-016-0264-2)
Confidentiality	“The principal investigator (N.H.) delayed the registration of the study until data acquisition was completed for confidentiality reasons concerning the study methods, especially the magnetic resonance with the related morphometric measurements.“ (doi: 10.1371/journal.pone.0136375)
Logistic/ Administrative issues	<p>“Because of administrative problems, release of registration occurred about six months after study start. The authors confirm that all ongoing and related trials for this intervention are registered.“ (doi: 10.1371/journal.pone.0220436)</p> <p>“Due to organisational changes in the research project shortly before the start of the recruitment we put great efforts into avoiding a delayed start of the data collection in the cooperating inpatient units, which resulted in retrospective study registration and a delayed publication of our study protocol.“ (doi: 10.1371/journal.pone.0186967)</p> <p>„Registration of the trial was delayed after the enrollment of the first patient due to an administrative error. The authors confirm that all ongoing and related trials for this intervention are registered.“ (doi: 10.1371/journal.pone.0140584)</p>

229

230

231 **Discussion**

232 In this study we show that in a sample of 956 results publications from retrospectively registered
 233 clinical studies led by German UMCs and completed between 2009 and 2017, only a small number of
 234 publications (5%) make the retrospective nature of the registration transparent, and even fewer
 235 (2%) explain the reasons for retrospective registration. To our knowledge, two studies have
 236 previously quantified the reporting of retrospective registration: Al-Durra et al. (17) found in a
 237 sample of 286 publications in ICMJE member journals and published in 2018 that only three percent
 238 (8/286) of papers of retrospectively registered trials in their sample include justifications or
 239 explanations for delayed registration. Similarly, Loder et al. (18), in their analysis of 70 papers

240 submitted to the British Medical Journal from 2012-2015 and rejected for registration issues, found
241 that three percent (2/70) disclosed the registration problem when published in another journal. Our
242 study finds a slightly lower percentage of two percent for explanations of the reasons for
243 retrospective registration, but a higher percentage of five percent for disclosure in a larger sample
244 representing a broader selection of journals and extended time frame.
245 We found that publications were not significantly more often prospectively registered when they
246 were published in ICMJE member journals or in journals following ICMJE recommendations, but
247 showed a significantly higher rate of TRN reporting. A similar result was found by Al-Durra et al. (17).
248 Further, we found that transparent reporting of retrospective registration does not happen
249 significantly more often in publications in ICMJE member journals, and is even happening at a
250 significantly lower rate in journals listed as following ICMJE recommendations.

251 There were different reasons for retrospective registration brought forth by authors, many of which
252 have been described previously (15,17,18,24). In some cases, authors raise points that lie outside
253 their direct responsibility, such as delays caused by the registry or research not being legally
254 required to be preregistered. Several other reasons provided were within authors' control, such as
255 logistic and administrative issues, miscommunication between researchers or unawareness of
256 registration policies. In some cases, authors report registering a study to meet journal editorial
257 policies even though registration would not be required for the kind of research otherwise. This is
258 also possibly reflected in the fact that almost a third (31%) of retrospectively registered studies in
259 our sample have been registered between study completion and publication. In one publication, the
260 authors transparently describe that the registration occurred only when "results suggested a
261 publication and further continuation of this research", which has been previously described as
262 "selective registration bias" (17) and is explicitly called out in ICMJE guidance as it "meets none of
263 the purposes of preregistration" (5). Another identified theme revolves around the confidentiality of
264 methods – however, in this case many other details about the trial could have been preregistered.

265 *Limitations*

266 For feasibility and data quality reasons, our study was based on an existing validated dataset,
267 containing only trials led by German UMCs, which might limit its generalizability to other regions.
268 However, the sample also contained multi-center trials with other countries involved and is larger
269 and from a wider variety of journals compared to previous studies (17,18). Our analysis of
270 retrospective registration is based on trial start dates and registration dates as provided by the two
271 registries used for sampling: Clinicaltrials.gov and DRKS. It is possible that authors did not update
272 their registry entries when delays to the start date occurred. For example, we did not specifically
273 follow up cases in which authors wrote that a trial was registered prospectively, but the registry
274 dates did not reflect that statement. In order not to reduce the sample size, we also did not correct
275 for varying follow-up in the identification of result publications, e.g., by limiting our analysis to
276 publications published within 2 years of trial completion. However, this means that the newer trials
277 in the sample (i.e., years 2016, 2017) might not reflect the complete research output of those years
278 as some trials may not have been published by the end of follow-up in 2020 and were therefore
279 excluded from the analysis. The numbers presented in Figures 2 and 3 may overestimate the
280 improvements in prospective registration as trials reporting results on time might likely generally
281 show a higher quality of registration conduct and might therefore be registered prospectively at a
282 higher rate.

283 In our analyses involving the classification into ICMJE-following and non-following journals, we relied
284 on the data provided on the ICMJE website (icmje.org), which are self-reported by journals, i.e., a
285 journal must write to the ICMJE that they want to be included in the list. Thus, there are some
286 journals missing in the ICMJE data and therefore in our dataset. For ICMJE member journals (n=12)
287 on the other hand, there is a complete listing available.

288

289 *Conclusion*

290 The Declaration of Helsinki and other guidelines for responsible clinical research unanimously
291 recommend prospective registration of all clinical research (2). For clinical trials regulated by drug
292 and device regulatory authorities, this was codified into law (4). A major aim of prospective
293 registration is to minimize the risk of undisclosed changes to the protocol after the study started and
294 first results are analyzed. When registration happens retrospectively, this major goal is not
295 addressed. The reporting of study registration is generally considered a best practice to make a
296 study more trustworthy. In the case of retrospective registration, in contrast, reporting registration
297 without transparency on the retrospective nature should rather raise concerns as readers might
298 wrongly interpret the mentioning of registration as a quality criterion. This could be considered
299 “performative reproducibility”, i.e., the “pretence of reproducibility without the reality” (25). Journal
300 editors and reviewers could enforce explicit reporting and explanation of retrospective registration,
301 but we found that this rarely happens. To fulfill the ICMJE requirements on reporting retrospective
302 registration, a simple note in the registration statement of the paper would suffice, such as: “This
303 study was retrospectively registered as [TRN] at [Registry], [X] days after the trial started because
304 [Reason]”.

305

306

307 **Ethics approval**

308 Not applicable

309

310 **Contributorship statement**

311 Martin Haslberger – Conceptualization, methodology, investigation, analysis, writing - original draft,
312 project management

313 Stefanie Gestrich – Methodology, investigation

314 Daniel Strech – Conceptualization, methodology, supervision, writing – review and editing, funding
315 acquisition

316

317

318 **Competing interests**

319 The authors declare no competing interests.

320

321 **Funding**

322 This work was partly funded under a grant from the Federal Ministry of Education and Research of
323 Germany (Bundesministerium fuer Bildung und Forschung - BMBF) [01PW18012]. The funder was
324 not involved in the study design, data collection, analysis, or interpretation, writing of the
325 manuscript, or the decision to submit for publication.

326

327 **Data sharing statement**

328 All code and the data for this study are available at <https://github.com/mhaslberger/retrospective->
329 registration. Data are also available in an OSF repository (<https://osf.io/8g5cf/>).

330

331 **Acknowledgments**

332 We thank Maia Salholz-Hillel for conceptual feedback and technical support. We thank Martin R.

333 Holst and Dr. Delwen Franzen for feedback on the manuscript.


334

335 **References**

- 336 1. Simes RJ. Publication bias: the case for an international registry of clinical trials. *J Clin Oncol*.
337 1986 Oct;4(10):1529–41.
- 338 2. WMA. World Medical Association: Declaration of Helsinki - Ethical Principles for Medical
339 Research involving Human Subjects [Internet]. 2018. Available from: [https://www.wma.net/policies-](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/)
340 [post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/)
- 341 3. World Health Organization. International standards for clinical trial registries: the
342 registration of all interventional trials is a scientific, ethical and moral responsibility [Internet].
343 version 3.0. Geneva: World Health Organization; 2018 [cited 2022 Feb 1]. 48 p. Available from:
344 <https://apps.who.int/iris/handle/10665/274994>
- 345 4. European Medicines Agency. Regulation (EU) No 536/2014 of the European Parliament and
346 of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing
347 Directive 2001/20/EC [Internet]. Jan 31, 2022. Available from:
348 <http://data.europa.eu/eli/reg/2014/536/2022-01-31>
- 349 5. ICMJE. International Committee of Medical Journal Editors Recommendations for the
350 Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals [Internet]. [cited
351 2021 Oct 18]. Available from: <http://www.icmje.org/icmje-recommendations.pdf>
- 352 6. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration:
353 a statement from the International Committee of Medical Journal Editors. *Lancet Lond Engl*. 2004
354 Sep 11;364(9438):911–2.
- 355 7. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010
356 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*.
357 2010 Mar 23;340(mar23 1):c869–c869.
- 358 8. Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good Publication
359 Practice for Communicating Company-Sponsored Medical Research: GPP3. *Ann Intern Med*. 2015
360 Sep 15;163(6):461–4.
- 361 9. Zarin DA, Keselman A. Registering a Clinical Trial in ClinicalTrials.gov. *Chest*. 2007
362 Mar;131(3):909–12.
- 363 10. Trinquart L, Dunn AG, Bourgeois FT. Registration of published randomized trials: a systematic
364 review and meta-analysis. *BMC Med*. 2018 Oct 16;16(1):173.
- 365 11. Birajdar AR, Bose D, Nishandar TB, Shende AA, Thatte UM, Gogtay NJ. An audit of studies
366 registered retrospectively with the Clinical Trials Registry of India: A one year analysis. *Perspect Clin*
367 *Res*. 2019 Mar;10(1):26–30.
- 368 12. Scott A, Rucklidge JJ, Mulder RT. Is Mandatory Prospective Trial Registration Working to
369 Prevent Publication of Unregistered Trials and Selective Outcome Reporting? An Observational Study
370 of Five Psychiatry Journals That Mandate Prospective Clinical Trial Registration. Wicherts JM, editor.
371 *PLOS ONE*. 2015 Aug 19;10(8):e0133718.
- 372 13. Mann E, Nguyen N, Fleischer S, Meyer G. Compliance with trial registration in five core
373 journals of clinical geriatrics: a survey of original publications on randomised controlled trials from
374 2008 to 2012. *Age Ageing*. 2014 Nov;43(6):872–6.


- 375 14. Smail-Faugeron V, Fron-Chabouis H, Durieux P. Clinical trial registration in oral health
376 journals. *J Dent Res*. 2015 Mar;94(3 Suppl):8S-13S.
- 377 15. Harriman SL, Patel J. When are clinical trials registered? An analysis of prospective versus
378 retrospective registration. *Trials*. 2016 Apr 15;17:187.
- 379 16. Boughton S. Retrospectively registered trials: the Editors' dilemma [Internet]. *Research in*
380 *progress blog*. 2016 [cited 2022 Jul 21]. Available from:
381 [https://blogs.biomedcentral.com/bmcblog/2016/04/15/retrospectively-registered-trials-editors-](https://blogs.biomedcentral.com/bmcblog/2016/04/15/retrospectively-registered-trials-editors-dilemma/)
382 [dilemma/](https://blogs.biomedcentral.com/bmcblog/2016/04/15/retrospectively-registered-trials-editors-dilemma/)
- 383 17. Al-Durra M, Nolan RP, Seto E, Cafazzo JA. Prospective registration and reporting of trial
384 number in randomised clinical trials: global cross sectional study of the adoption of ICMJE and
385 Declaration of Helsinki recommendations. *BMJ*. 2020 Apr 14;m982.
- 386 18. Loder E, Loder S, Cook S. Characteristics and publication fate of unregistered and
387 retrospectively registered clinical trials submitted to The BMJ over 4 years. *BMJ Open*. 2018 Feb
388 16;8(2):e020037.
- 389 19. Wieschowski S, Riedel N, Wollmann K, Kahrass H, Müller-Ohlraun S, Schürmann C, et al.
390 Result dissemination from clinical trials conducted at German university medical centers was
391 delayed and incomplete. *J Clin Epidemiol*. 2019 Nov;115:37–45.
- 392 20. Riedel N, Wieschowski S, Bruckner T, Holst MR, Kahrass H, Nury E, et al. Results
393 dissemination from completed clinical trials conducted at German university medical centers
394 remained delayed and incomplete. The 2014 –2017 cohort. *J Clin Epidemiol*. 2022 Apr;144:1–7.
- 395 21. [dataset] Haslberger M, Gestrich S, Strech D. Reporting of Retrospective Registration in
396 Clinical Trial Publications [Internet]. 2023. Available from: <https://osf.io/8g5cf/>
- 397 22. ICMJE. Journals stating that they follow the ICMJE Recommendations [Internet]. [cited 2022
398 Apr 7]. Available from: <http://www.icmje.org/journals-following-the-icmje-recommendations/>
- 399 23. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The
400 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:
401 guidelines for reporting observational studies. *Lancet Lond Engl*. 2007 Oct 20;370(9596):1453–7.
- 402 24. Hunter KE, Seidler AL, Askie LM. Prospective registration trends, reasons for retrospective
403 registration and mechanisms to increase prospective registration compliance: descriptive analysis
404 and survey. *BMJ Open*. 2018 Mar 1;8(3):e019983.
- 405 25. Buck S. Beware performative reproducibility. *Nature*. 2021 Jul 8;595(7866):151–151.
- 406

407 Figure 1: Flowchart of in-/exclusion of studies. From the 1038 trials that were retrospectively
408 registered in Clinicaltrials.gov or DRKS, we excluded 5 publications that clearly did not report clinical
409 study results (e.g., secondary analyses of CT data) and another 77 that reported EudraCT entries in
410 the publications, resulting in 956 retrospectively registered studies from a total dataset of 1927 (971
411 + 956) studies.



412
413
414

415 Figure 2: Percentage of retrospectively registered (RR) trials over time (per study start year). GAM
 416 (generalized additive model) smoother laid over (blue) with 95% confidence interval. Bubble sizes
 417 indicate the number of trials per year included in the dataset.




418

419

420

421 Figure 3: Percentage of retrospectively registered trials reporting retrospective registration
 422 transparently in the publication over time (per study publication year). GAM (generalized additive
 423 model) smoother laid over (blue) with 95% confidence interval. Bubble sizes indicate the number of
 424 trials per year included in the dataset. Starting in 2013, some authors begin to report retrospective
 425 registration. 15% of publications of retrospectively registered trials from 2020 transparently report
 426 retrospective registration. Four trials were published before 2009 – in all those cases the study
 427 completion dates provided in the registry were after 2009. Study start dates were before 2005 and
 428 studies were registered in 2005 (3/4) or later (1/4).



Year (Pub.)	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
n	2	0	2	12	40	111	144	199	205	240	278	234	215	160	85
RRR	0	0	0	0	0	0	0	1	0	5	12	9	10	4	6
% RRR	0		0	0	0	0	0	0.9	0	4.4	8.5	8.7	11.2	8	15.4

429